Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis

Key Points Question Is guselkumab dosing every 16 weeks noninferior to standard dosing every 8 weeks for maintenance of psoriasis disease control, defined as a Psoriasis Area and Severity Index lower than 3 at week (W)68, in super responders (SRes)? Findings This phase 3b clinical trial randomized 149 guselkumab SRes to guselkumab every 16 weeks dosing and 148 SRes to every 8 weeks dosing at W28 and demonstrated noninferiority of every 16 weeks dosing for maintenance of disease control, meeting the primary end point; clinical effects corresponded with immunologic changes. Meaning The GUIDE randomized clinical trial is the first to demonstrate that disease activity in patients with early complete skin clearance may be controlled with an extended guselkumab dosing interval.

• Publication year

  2024

• Venue

  JAMA dermatology

• Publication date

  2024-07-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamadermatol.2024.2463PMID 39083288PMCID 11292573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis

  2023cited by this paper
• Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation

  2023cited by this paper
• Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study

  2023cited by this paper
• Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

  2022cited by this paper
• National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure

  2022cited by this paper
• Resident Memory T Cells in Psoriasis: Key to a Cure?

  2022cited by this paper
• Differential Changes in Inflammatory Mononuclear Phagocyte and T Cell Profiles within Psoriatic Skin during Treatment with Guselkumab versus Secukinumab.

  2021cited by this paper
• IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

  2021cited by this paper
• German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations

  2021cited by this paper
• Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review

  2021cited by this paper
• Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.

  2021cited by this paper
• Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study

  2020cited by this paper
• Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.

  2019cited by this paper
• CD8 resident memory T cells with interleukin 17A‐producing potential are accumulated in disease‐naïve nonlesional sites of psoriasis possibly in correlation with disease duration

  2019cited by this paper
• Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study.

  2019cited by this paper
• Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)

  2019cited by this paper
• Significance of IL-17A-producing CD8+CD103+ skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course.

  2019cited by this paper
• Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis

  2018cited by this paper
• &bgr;‐Defensin 2 is a responsive biomarker of IL‐17A–driven skin pathology in patients with psoriasis

  2017cited by this paper
• Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial

  2017cited by this paper
• Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA

  2017cited by this paper
• Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR)

  2017cited by this paper
• Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

  2014cited by this paper
• Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.

  2011cited by this paper
• Psoriasis

  1986cited by this paper
• Psoriasis

  1906cited by this paper

• Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial.

  2026cites this paper
• High-Dose, Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care?

  2026cites this paper
• Perspectives and Real-World Clinical Practice of Portuguese Dermatologists on Biologic Dose Spacing in Psoriasis: Results from a Nationwide Survey.

  2026cites this paper
• Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial.

  2026cites this paper
• T cell-centric immunopathogenesis of psoriasis

  2025cites this paper
• Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits

  2025cites this paper
• A psoriasis cure could be in touching distance

  2025cites this paper
• Skin immune microenvironment in psoriasis: from bench to bedside

  2025cites this paper
• Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study

  2025cites this paper
• Hypothalamic pituitary adrenal axis hormone changes during IL-17A inhibition with secukinumab in patients with psoriasis.

  2025cites this paper
• Super Responders in Plaque Psoriasis: A Real-World, Multi-Agent Analysis Showing Bimekizumab Associated with the Highest Odds of PASI = 0 at Week 12

  2025cites this paper
• From reactive to predictive: Advancing biologic dosing in dermatology

  2025cites this paper
• Drug survival, effectiveness, and safety of guselkumab for moderate-to-severe psoriasis for up to 4 years.

  2025cites this paper
• Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing

  2025cites this paper
• Personalising biologic therapy in psoriasis: Development, validation and user-testing of a precision dosing dashboard.

  2025cites this paper
• Disease Modification in Psoriasis: Future Prospects for Long-Term Remission

  2025cites this paper
• The Translational Dermatology Initiative: Aiming at a New Disease Classification of Inflammatory Skin Diseases

  2025cites this paper
• Novel Therapeutic Targets in the Management of Psoriatic Disease.

  2025cites this paper
• Treatment Options for the Comorbidity of Multiple Sclerosis With Other Chronic Inflammatory Diseases.

  2025cites this paper
• Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysis

  2025cites this paper
• Skin Barrier Dysfunction in Chronic Dermatoses: From Pathophysiology to Emerging Therapeutic Strategies

  2025cites this paper
• Long‐Term Impact of Guselkumab on Skin, Sexuality, and Perceived Stigmatization in Patients With Psoriasis in Routine Clinical Practice: Week 76 Effectiveness and Safety Results From the Prospective German Multicenter G‐EPOSS Study

  2025influential citation
• Quoi de neuf en thérapeutique dermatologique ?

  2024cites this paper
• Time to Loss of Disease Control following Guselkumab Withdrawal in Relation to Initial Speed of Response: A post hoc Analysis of the VOYAGE 2 Trial

  2024cites this paper
• Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience

  2024influential citation
• Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis.

  2024cites this paper
• Quoi de neuf en recherche ?

  2024cites this paper
• Errors in Figures 1 and 3.

  2024cites this paper
• Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis

  2024cites this paper